Revolution Medicines, Inc. Common Stock
RVMD
$211.74
-1.36%
Revolution Medicines, Inc. is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers, leveraging its proprietary structure-based drug discovery platform to create small molecules that bind to unconventional sites on RAS proteins. As a leader in the emerging RAS-targeting space, the company is distinguished by its broad pipeline of RAS(ON) inhibitors designed for monotherapy and combination use. The current investor narrative centers on the company's transformative Phase 3 pancreatic cancer data, which doubled survival versus chemotherapy, and its subsequent $2.2 billion capital raise to fund the pipeline, driving a massive re-rating of the stock in 2026. However, the debate remains whether the clinical promise justifies the valuation for a pre-revenue biotech with significant dilution and execution risks.…
RVMD
Revolution Medicines, Inc. Common Stock
$211.74
Related headlines
Investment Opinion: Should I buy RVMD Today?
Rating: Buy. The thesis is that Revolution Medicines' transformative Phase 3 data and robust pipeline justify the premium valuation, with strong analyst support and a clear path to commercialization. The consensus rating is 'Strong Buy' with an average target of $221.90, implying 8.9% upside, and the high target of $291.00 suggests even greater potential.
Sign up to view all
RVMD 12-Month Price Forecast
The AI assessment is bullish, driven by the transformative clinical data and strong analyst support. However, the confidence is medium due to the pre-revenue status and high valuation. The stock's momentum and relative strength suggest continued upside, but any negative news could trigger a sharp correction. I would upgrade to high confidence if the company reports additional positive data or secures a partnership, and downgrade to neutral if a trial fails or the stock breaks below key support levels.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Revolution Medicines, Inc. Common Stock's 12-month outlook, with a consensus price target around $221.90 and implied upside of +4.8% versus the current price.
Average Target
$221.90
0 analysts
Implied Upside
+4.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$151 - $291
Analyst target range
Revolution Medicines is covered by 21 analysts, with a consensus recommendation of 'Strong Buy' (mean rating of 1.27). The average price target is $221.90, implying approximately 8.9% upside from the current price of $203.71. The distribution is heavily bullish, with no sell ratings and only a few holds, reflecting strong conviction in the company's clinical prospects.
Bulls vs Bears: RVMD Investment Factors
Revolution Medicines presents a compelling bull case driven by transformative clinical data, strong analyst support, and a well-funded pipeline, but the bear case centers on its pre-revenue status, premium valuation, and significant execution risks. Currently, the bull case has stronger evidence given the Phase 3 success and the $2.2 billion war chest, but the stock's valuation leaves no margin for error. The most important tension is whether the clinical promise of daraxonrasib can translate into commercial success and justify the 9.28x price-to-book ratio, or if any setback will trigger a sharp de-rating. Investors are betting on a future blockbuster, and the next 12 months will be critical in validating that bet.
Bullish
- Transformative Phase 3 Pancreatic Data: The Phase 3 trial for daraxonrasib doubled survival versus chemotherapy, a breakthrough in a notoriously difficult-to-treat cancer. This data drove a massive re-rating, with the stock up 465.5% over the past year, and positions the drug as a potential standard-of-care.
- Strong Analyst Conviction: With 21 analysts covering, the consensus is 'Strong Buy' (mean rating 1.27), and the average price target of $221.90 implies 8.9% upside. No sell ratings and only a few holds indicate high confidence in the pipeline's commercial potential.
- Robust Balance Sheet Post-Raise: The $2.2 billion capital raise in April 2026 significantly de-risks the pipeline, providing funding for late-stage trials and potential commercialization. The current ratio of 7.14x and low debt-to-equity of 0.10x indicate strong liquidity to support operations.
- Leadership in RAS-Targeting Space: As a pioneer in RAS(ON) inhibitors, the company has a broad pipeline targeting RAS-addicted cancers, a large unmet medical need. This first-mover advantage could lead to multiple blockbuster drugs, justifying the premium valuation.
Bearish
- Pre-Revenue with Escalating Losses: The company has zero revenue, and Q1 2026 net loss widened to $453.8 million from $213.4 million a year ago, a 113% increase. R&D expenses surged 67% to $344.0 million, indicating accelerating cash burn with no near-term revenue visibility.
- Premium Valuation with No Earnings: The price-to-book ratio of 9.28x is well above the biotech industry average of 4-5x, reflecting high expectations. With negative earnings, the stock's valuation is based on speculative future cash flows, leaving little room for disappointment.
- Dilution from Capital Raise: The $2.2 billion raise, while de-risking, significantly diluted existing shareholders. Shares outstanding increased from 188.1 million in Q1 2025 to 198.1 million in Q1 2026, a 5.3% increase, and further dilution may be needed as cash burn continues.
- Clinical and Regulatory Execution Risk: As a clinical-stage company, any trial failure or regulatory setback could be catastrophic. The stock's 24.95% max drawdown over the past year highlights the volatility, and the high beta of 1.403 amplifies market swings.
RVMD Technical Analysis
Revolution Medicines is in a powerful sustained uptrend, with the stock up 465.5% over the past year, dramatically outperforming the S&P 500's 20.4% gain. The current price of $203.71 sits at 97.6% of its 52-week range (low of $35.42, high of $208.76), indicating the stock is trading near its highs, reflecting strong momentum but also potential overextension. The 6-month price change of 111.5% underscores the acceleration in the trend, which has been driven by clinical catalysts and a sector-wide re-rating of RAS-targeting assets.
Beta
1.40
1.40x market volatility
Max Drawdown
-24.9%
Largest decline past year
52-Week Range
$35-$220
Price range past year
Annual Return
+485.6%
Cumulative gain past year
| Period | RVMD Return | S&P 500 |
|---|---|---|
| 1m | +15.5% | +1.9% |
| 3m | +39.7% | +2.3% |
| 6m | +107.9% | +10.6% |
| 1y | +485.6% | +19.5% |
| ytd | +168.0% | +11.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RVMD Fundamental Analysis
Revolution Medicines is a pre-revenue company, with zero revenue in the most recent quarter (Q1 2026) and only $7.0 million in collaboration revenue reported for the trailing twelve months, highlighting its dependence on pipeline success. Research and development expenses have surged from $205.7 million in Q1 2025 to $344.0 million in Q1 2026, a 67% increase, reflecting the advancement of late-stage trials. The company's net loss widened to $453.8 million in Q1 2026 from $213.4 million in the year-ago quarter, with EPS of -$2.29, indicating escalating cash burn as the pipeline progresses.
Quarterly Revenue
$0.0B
2026-03
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-1.1B
Last 12 Months
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RVMD Overvalued?
Given the company's negative net income, the price-to-sales ratio is not meaningful (PS ratio of 0), so I selected the price-to-book ratio as the primary valuation metric, which stands at 9.28x. This is a premium to the biotech industry average of around 4-5x, reflecting the market's high expectations for the pipeline's commercial potential. The forward PE of -30.86x and trailing PE of -13.39x are both negative, but the gap between them suggests the market expects losses to narrow as revenue from potential drug approvals begins to materialize.
PE
-13.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-13.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. The company is pre-revenue, with zero product sales, and its net loss widened to $453.8 million in Q1 2026, up from $213.4 million a year ago, reflecting a 113% increase in cash burn. R&D expenses surged 67% to $344.0 million, and free cash flow was -$1.07 billion over the trailing twelve months, indicating heavy reliance on external funding. While the $2.2 billion raise provides a cushion, the company's current ratio of 7.14x and low debt-to-equity of 0.10x are healthy, but ongoing losses will require further dilution or partnerships to sustain operations. The negative EPS of -$2.29 in Q1 2026 and the widening gap between forward and trailing PE (-30.86x vs -13.39x) suggest the market expects losses to narrow, but any delay in commercialization would strain the balance sheet.
FAQ
The key risks are financial, competitive, and clinical. Financially, the company is pre-revenue with a net loss of $453.8 million in Q1 2026, and it relies on external funding, which could lead to dilution. Competitively, other companies are developing RAS-targeting drugs, and Merck's $6.7 billion acquisition of Terns Pharmaceuticals highlights the threat. Clinically, any trial failure or regulatory delay could be catastrophic, as the stock's high beta of 1.403 amplifies market swings. The most severe risk is a clinical setback, which could send the stock down 25-80% from current levels.
The 12-month forecast is bullish, with a base case probability of 50% targeting $200-$240, a bull case probability of 30% targeting $250-$291, and a bear case probability of 20% targeting $150-$180. The most likely scenario is the base case, where the stock trades around the analyst average target of $221.90, assuming the pipeline progresses without major setbacks. The bull case would require additional positive data or a partnership, while the bear case would be triggered by a clinical failure or competitive threat. Overall, the stock has a positive expected return, but with significant volatility.
RVMD is overvalued relative to its fundamentals, as it has zero revenue and negative earnings. The price-to-book ratio of 9.28x is well above the biotech industry average of 4-5x, indicating the market is pricing in significant future success. The forward PE of -30.86x suggests the market expects losses to narrow, but the stock's valuation is based on speculative pipeline potential. Compared to its own history, the stock has re-rated dramatically, with a 465.5% gain over the past year, so it is trading at a premium to its historical valuation. The market is expecting daraxonrasib to become a blockbuster, and any disappointment could lead to a sharp de-rating.
RVMD is a good buy for investors with a high risk tolerance and a long-term horizon, given its transformative clinical data and strong analyst support. The average analyst target of $221.90 implies 8.9% upside, but the stock is trading at a premium valuation with no revenue, so the risk is substantial. The biggest downside risk is a clinical failure, which could send the stock to the 52-week low of $35.42, a -82.6% decline. For investors who believe in the RAS-targeting potential and can withstand volatility, it could be a rewarding investment, but it is not suitable for conservative investors.
RVMD is more suitable for long-term investment, given its clinical-stage nature and the time required for drug development and commercialization. The stock's high beta of 1.403 and 24.95% max drawdown make it too volatile for short-term trading, and its pre-revenue status means fundamental catalysts are years away. For long-term investors, the potential for daraxonrasib to become a standard-of-care treatment could drive significant returns, but they must be prepared for multi-year holding periods and substantial drawdowns. A minimum holding period of 3-5 years is recommended to allow the pipeline to mature and generate revenue.